NCT05050318View on ClinicalTrials.gov

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

November 10, 2021

Study Completion Date

November 10, 2021

Conditions
Influenza ImmunizationHealthy Volunteers
Interventions
BIOLOGICAL

Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation

Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)

BIOLOGICAL

Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation

Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)

Trial Locations (2)

40004

Investigational Site Number :8400001, Bardstown

84121

Investigational Site Number :8400002, Salt Lake City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively | Biotech Hunter | Biotech Hunter